Debt-to-equity improved to 1.17 in 2026Q2 from 1.83 in 2024Q1, yet total debt of $2.4B and goodwill of $2.5B (42% of assets) highlight leverage and impairment risks.
| Total Current Assets | 2.47B | 2.89B | 1.89B | 1.46B | 1.34B | 1.18B | 1.29B | 870.68M |
| Cash & Short-Term Investments | 550.38M | 88.37M | 61.25M | 13.07M | 13.63M | 46.73M | 262M | 18.3M |
| Cash Only | 550.38M | 88.37M | 61.25M | 13.07M | 13.63M | 46.73M | 262M | 18.3M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.31B | 1.07B | 1.15B | 1.01B | 868.35M | 805M | 700.84M | 622.28M |
| Days Sales Outstanding | 29.79 | 30.31 | 37.23 | 41.8 | 41.05 | 43.87 | 45.84 | 50.19 |
| Inventory | 575.01M | 815.18M | 640.57M | 402.78M | 430.52M | 299.22M | 300.06M | 198.47M |
| Days Inventory Outstanding | 18.77 | 26.12 | 24.16 | 19.89 | 24.68 | 20.04 | 24.17 | 19.63 |
| Other Current Assets | 20.4M | 899.01M | 24.59M | 13.19M | 13.51M | 12.66M | 16.41M | 23.37M |
| Total Non-Current Assets | 3.52B | 3.52B | 4.03B | 4.08B | 4.1B | 4.33B | 3.25B | 2.95B |
| Property, Plant & Equipment | 380.84M | 376.32M | 500.03M | 513.35M | 475.27M | 524.64M | 450.71M | 432.55M |
| Fixed Asset Turnover | 39.17x | 34.31x | 22.53x | 17.19x | 16.24x | 12.77x | 12.38x | 10.46x |
| Goodwill | 2.54B | 2.55B | 2.67B | 2.61B | 2.58B | 2.66B | 1.67B | 1.41B |
| Intangible Assets | 468.31M | 557.55M | 811.48M | 881.48M | 975.86M | 1.11B | 1.1B | 1.07B |
| Long-Term Investments | 55.74M | 8.2M | 670K | 720K | 736K | 2.66M | 2.48M | 2.37M |
| Other Non-Current Assets | 107.69M | 31.51M | 43.8M | 72.12M | 68.93M | 35.78M | 32.22M | 34.56M |
| Total Assets | 5.99B | 6.41B | 5.93B | 5.53B | 5.44B | 5.51B | 4.54B | 3.82B |
| Asset Turnover | 2.33x | 2.01x | 1.90x | 1.60x | 1.42x | 1.21x | 1.23x | 1.19x |
| Asset Growth % | 19.75% | 8.22% | 7.11% | 1.68% | -1.31% | 21.41% | 18.96% | - |
| Total Current Liabilities | 1.56B | 1.85B | 1.43B | 1.25B | 932.51M | 892.16M | 742.79M | 621.97M |
| Accounts Payable | 1.09B | 1.22B | 941.29M | 641.61M | 526.92M | 408.11M | 355.75M | 252.75M |
| Days Payables Outstanding | 31.56 | 39.02 | 35.5 | 31.68 | 30.21 | 27.33 | 28.65 | 24.99 |
| Short-Term Debt | 41.45M | 52.34M | 48.73M | 32.27M | 30.41M | 40.54M | 22.5M | 18.48M |
| Deferred Revenue (Current) | 39.6M | 9.04M | 11M | 30.85M | 29.04M | 10.49M | 22.76M | 3.31M |
| Other Current Liabilities | -13.08M | 297.19M | 98.84M | 118.14M | 80.73M | 95.87M | 16.18M | 14.19M |
| Current Ratio | 1.59x | 1.57x | 1.33x | 1.17x | 1.44x | 1.32x | 1.74x | 1.40x |
| Quick Ratio | 1.22x | 1.12x | 0.88x | 0.84x | 0.98x | 0.99x | 1.33x | 1.08x |
| Cash Conversion Cycle | 16.99 | 17.41 | 25.89 | 30.01 | 35.53 | 36.57 | 41.35 | 44.83 |
| Total Non-Current Liabilities | 2.37B | 2.68B | 2.85B | 3.67B | 3.72B | 3.82B | 3.06B | 2.49B |
| Long-Term Debt | 2.15B | 2.46B | 2.56B | 3.33B | 3.36B | 3.39B | 2.67B | 2.16B |
| Capital Lease Obligations | 584.2M | 149.96M | 212.6M | 224.18M | 204.91M | 252.09M | 211.95M | 190.15M |
| Deferred Tax Liabilities | 18.42M | 6.18M | 0 | 23.67M | 79.39M | 98.16M | 121.64M | 65.68M |
| Other Non-Current Liabilities | 76.61M | 66.56M | 71.76M | 91.94M | 75.94M | 77.04M | 57.98M | 65.46M |
| Total Liabilities | 3.93B | 4.53B | 4.27B | 4.92B | 4.66B | 4.71B | 3.81B | 3.11B |
| Total Debt | 2.39B | 2.71B | 2.9B | 3.67B | 3.68B | 3.77B | 2.97B | 2.44B |
| Net Debt | 1.84B | 2.62B | 2.84B | 3.66B | 3.66B | 3.72B | 2.71B | 2.43B |
| Debt / Equity | 1.16x | 1.44x | 1.76x | 5.99x | 4.69x | 4.71x | 4.04x | 3.44x |
| Debt / EBITDA | 3.74x | 5.89x | 7.07x | 10.50x | 9.39x | 8.70x | 8.58x | 11.20x |
| Net Debt / EBITDA | 2.88x | 5.70x | 6.92x | 10.46x | 9.35x | 8.59x | 7.82x | 11.12x |
| Interest Coverage | 3.14x | 1.88x | 0.85x | 0.45x | 0.80x | 1.42x | 1.19x | 0.38x |
| Total Equity | 2.06B | 1.89B | 1.65B | 612.55M | 784.08M | 800.46M | 735.38M | 710.23M |
| Equity Growth % | 62.31% | 14.22% | 169.63% | -21.88% | -2.05% | 8.85% | 3.54% | - |
| Book Value per Share | 9.34 | 8.58 | 8.56 | 3.58 | 4.58 | 4.68 | 4.30 | 4.15 |
| Total Shareholders' Equity | 2.05B | 1.88B | 1.65B | 584.74M | 754.78M | 774.82M | 704.98M | 656.87M |
| Common Stock | 1.98M | 1.92M | 1.74M | 1.18M | 1.18M | 1.18M | 745.17M | 745.88M |
| Retained Earnings | 38.43M | -74.65M | -222.16M | -200.32M | -45.72M | 971K | -51.75M | -94.28M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4.18M | -6.69M | 1.42M | 12.54M | 21.19M | 217K | 185K | 132K |
| Minority Interest | 9.48M | 11.3M | 3.73M | 27.81M | 29.31M | 25.65M | 30.39M | 53.36M |
Leverage and margin compression
Debt-to-equity fell from 1.83 in 2024Q1 to 1.17 in 2026Q2, while retained earnings turned positive at $38.4M, according to recent SEC filings, indicating a strengthening equity base.
The balance sheet is deleveraging steadily, with total debt reduced from $2.9B to $2.4B over the period, while equity expanded from $1.6B to $2.0B. This trend suggests that the company is using cash flow to pay down debt and retain earnings, a positive shift from the prior loss-making quarters. However, the absolute debt level remains high relative to equity, and the improvement is partly due to the low base of equity, so the trajectory is encouraging but not yet robust.
Total debt of $2.4B in 2026Q2 still represents 40% of total assets, with a debt-to-equity ratio of 1.17, as reported in financial statements, indicating significant financial risk.
Although the D/E ratio has improved from 1.83 to 1.17, the company remains highly leveraged, especially when compared to peers like Addus HomeCare (D/E 0.19) and LifeStance (0.13). The absolute debt level is substantial relative to the company's equity base, and with net margins of only 1.5%, interest coverage is likely thin. This leverage appears to be a legacy of the PharMerica acquisition and other roll-up strategies, and while it is being reduced, the pace may be slow given the modest profitability.
Goodwill of $2.5B accounts for 42% of total assets in 2026Q2, as per the balance sheet, while net PPE is only $380.8M, underscoring the asset-light, acquisition-driven model.
The asset mix is heavily weighted toward intangible assets, with goodwill alone exceeding the entire equity base. This suggests that the company's value is tied to acquired businesses, and any impairment could significantly erode equity. The low PPE relative to revenue indicates a service-oriented model with minimal fixed assets, which aligns with the labor-intensive nature of home health and pharmacy services. Investors should monitor goodwill for potential impairment triggers, especially if organic growth slows or reimbursement changes.
Retained earnings swung from -$246.1M in 2024Q1 to +$38.4M in 2026Q2, as reported in financial statements, marking a critical inflection point in equity quality.
The shift from accumulated deficits to positive retained earnings is a significant milestone, indicating that the company has generated enough cumulative profit to offset prior losses. This improvement is driven by the recent profitability turnaround, with net income turning positive in 2025. However, the equity base of $2.0B is still relatively small compared to total assets, and the company continues to use stock-based compensation, which dilutes shareholders. The positive retained earnings provide a cushion, but the equity quality remains dependent on sustained profitability.
Cash surged to $550.4M in 2026Q2 from $58.0M in 2024Q1, with the current ratio improving to 1.59, according to recent filings, indicating a stronger liquidity position.
The liquidity position has improved markedly, with cash now covering a significant portion of short-term obligations. The current ratio of 1.59 is above the 1.0 threshold, suggesting adequate short-term solvency. However, the company's operating margins are razor-thin, and the cash balance may be needed for debt repayments or acquisitions, so the buffer is not excessive. The improvement in cash is partly due to working capital management and positive operating cash flow, but the sustainability of this liquidity depends on maintaining cash generation.
With goodwill of $2.5B representing 42% of assets and equity of only $2.0B, a 20% impairment would wipe out a quarter of equity, as per balance sheet data, posing a hidden risk.
The balance sheet is highly sensitive to goodwill impairment, given the large acquisition-related intangibles. If the company's market value declines or cash flow projections weaken, an impairment charge could significantly reduce equity and increase leverage. This risk is not apparent from the headline D/E ratio but is a material distortion. Investors should monitor the company's market capitalization relative to book value and any indicators of underperformance in acquired segments.
Quick answers to the most common questions about buying BTSG stock.
As of 2025, BrightSpring Health Services, Inc. Common Stock (BTSG) had total assets of $6.41B including $2.89B in current assets.
BrightSpring Health Services, Inc. Common Stock (BTSG) carries total debt of $2.71B, offset by $88.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
BrightSpring Health Services, Inc. Common Stock (BTSG) has total shareholders' equity (book value) of $1.88B ($8.58 book value per share). Book value represents the net worth of the company belonging to common stock holders.
BrightSpring Health Services, Inc. Common Stock (BTSG) reported a current ratio of 1.57x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.